

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

| Manufacturer | Product | Reference Product | Generic Name | Strength | Dosage Form | DIN |
|-------------------|--------------------------|---------------------|--------------------------------|-----------|-------------|----------|
| Apotex Inc. | Apo-Valsartan | Diovan | valsartan | 40mg | tablet | 02371510 |
| Apotex Inc. | Apo-Memantine | Ebixa | memantine hydrochloride | 10mg | tablet | 02366487 |
| Auro Pharma Inc. | Auro-Cyclobenzaprine | Apo-Cyclobenzaprine | cyclobenzaprine hydrochloride | 10mg | tablet | 02348853 |
| Sanis Health Inc. | Lisinopril/HCTZ (Type Z) | Zestoretic | lisinopril/hydrochlorothiazide | 20mg/25mg | tablet | 02362961 |

Updated: September 23, 2011

